Abstract Right ventricular hypertrophy induced by chronic hypoxia is mainly due to a mechanical stress upon the ventricular wall secondary to pulmonary arterial hypertension. However, the hypoxic chronic activation of the sympathetic nervous system can contribute to the development of right ventricular hypertrophy either via myocardial adrenergic receptors and/or a vasoconstriction and remodeling of pulmonary arteries. To highlight the specific role of the sympathetic nervous system on hypoxia-induced right ventricular hypertrophy and particularly the efficiency of carvedilol, our study compared physiological, myocardial, and pulmonary arterial morphometric data in rats treated by α-(prazosin), or β-(propranolol) or αβ-(carvedilol) antagonist and exposed to chronic hypobaric hypoxia (2 weeks at 380 mmHg barometric pressure). In chronic hypoxia, both systolic right ventricular pressure and Fulton's ratio (right/ (left+septum) ventricular weight) were lower in rats treated by prazosin (−16.7 and −13.6%), propranolol (−28.6 and −12.7%) and carvedilol (−15.9 and −14.3%) respectively when compared to glucose (p<0.05). Surprisingly, prazosin was unable to reduce right ventricular hypertrophy induced by chronic hypoxia, whereas, left ventricular weight increased. Wall thickness index of pulmonary arteries increased in chronic hypoxia and was reduced by carvedilol. In conclusion, the hypoxia-induced activation of the adrenergic system participates in the development of right ventricular hypertrophy. Carvedilol is effective in reducing hypoxia-induced right ventricular hypertrophy, pulmonary arterial hypertension, and muscularization of pulmonary arteries.
Introduction
Exposure to chronic hypobaric hypoxia induces a pulmonary vasoconstriction and an increase in pulmonary artery pressure leading to right ventricular hypertrophy (RVH). RVH, as a response to an increased afterload of the right ventricle, could also be considered as an adaptation of the myocardial mass to the increase of intra-ventricular pressure [4, 36] . Chronic hypoxia induces a pulmonary arterial wall hypertrophy (fixed part of vascular resistances) as highlighted by the increase in wall thickness index (WTI) in rats acclimatized to hypoxia [8] . The mechanism of RVH is mainly due to a mechanical stress applied to the ventricular wall [7, 18] . However, the activation of the sympathetic nervous system (SNS) has been associated with ventricular hypertrophy [17, 32, 35] .
Part of the overload could be secondary to the activation of the pulmonary arterial α 1A -and α 1B -adrenergic receptors [20] . The activation of these receptors induces pulmonary vasoconstriction, pulmonary hypertension, right ventricular overload, and pulmonary arterial wall hypertrophy [31] . On the other hand, adrenergic agonists could directly induce a hypertrophy of the cardiomyocytes, as shown in vivo [32] or in vitro [2, 17] . Moreover, the acute hypoxia-induced activation of SNS leads to increased heart rate (HR) and cardiac output (CO). With prolonged exposure to hypoxia, HR and CO tend to decrease towards normoxic values, although the activation of SNS remains high. In fact, chronic activation of SNS induces a downregulation of adrenergic receptors [9, 19] , decreasing chronotropic response to β-adrenergic agonists and maximal heart rate [11, 29] .
These modifications may protect the myocardium by decreasing maximum cardiac work. They could be considered as homeostatic mechanisms contributing to the maintenance of myocardium tissue PO 2 , despite a decrease in oxygen supply [30] . Attempts have been made to reduce pulmonary hypertension and RVH by blocking the adrenergic pathways. α-antagonists are able to decrease pulmonary hypertension [5, 38] , but no study has evidenced an effect on RVH, and β-antagonists reduce pulmonary hypertension [25] and RVH [25, 26] . Carvedilol combines these α and β adrenergic antagonist effects of prazosin and propranolol. Its anti-adrenergic effects on left ventricular failure [15, 34] and its ability to treat or prevent cardiac failure in post infarction [41] or hypertension [6] have been extensively studied. However, carvedilol, as an α and β-adrenergic antagonist, has never been tested in the chronic hypoxic model of RVH or in compatible models of chronic cor pulmonale. We have hypothesized that SNS participates in the development of RVH. It could participate, either by a direct stimulation of α, β, or both myocardial adrenergic receptors and/or by an indirect way, via the stimulation of α-adrenergic receptors of pulmonary arteries, and, therefore, induction of pulmonary hypertension. Furthermore, carvedilol has some antioxidant effects, which could further reduce RVH and blunt other hypoxiainduced modifications [16] . Carvedilol has some other specific effects, such as antiproliferative [37] or antideposition of collagen [40] . To evidence a specific role of SNS on hypoxia-induced RVH and evaluate the efficacy of carvedilol and prazosin, the present study compared physiological, myocardial, and pulmonary arterial morphometric data in normoxia and chronic hypobaric hypoxia in rats treated by α-, β-, or αβ-antagonists. Prazosin, an α 1 -antagonist, propranolol, an unspecific β-antagonist, and carvedilol, an α 1 -and unspecific β-antagonist were used.
Materials and methods

Animal care and use
All animal experiments were performed by scientists certified by the French Ministry of Agriculture. Standard procedures and protocols were established according to the European Community guidelines (European act: 2001-486, 6 June 2001) and to the APS's Guiding Principles in the Care and Use of Animals. Rat chow and tap water were provided ad libitum. Ambient temperature (21±2°C) and humidity (49±3%) were controlled daily, inside and outside the hypobaric chamber. The chamber was opened to normoxia 1/2 h twice daily for treatment, cleaning, and food and water replacement. Rats were kept on a 12/12-h lighting schedule. Male Wistar rats (250 g) (Centre d'Elevage René Janvier, France) were divided into eight groups, four normoxic (Nx) and four hypoxic (Hx).
The Hx groups were exposed to chronic hypoxia in a hypobaric chamber (380 mmHg, 50.66 kPa, 5,500 m simulated altitude) for 2 weeks and bred in the same room as the Nx groups. Both Nx and Hx groups were divided into four other groups treated by prazosin 6 mg/kg/day (Prazosin, Sigma-Aldrich Chemie Gmbh, Germany) (NxPz and HxPz), propranolol 60 mg/kg/day (DL-propranolol P-0884, Sigma-Aldrich Chemie Gmbh, Germany) (NxPp and HxPp), carvedilol 20 mg/kg/day (Roche Diagnostics GmbH, Germany) (NxCv and HxCv) or vehicle (glucose) solution (NxCt and HxCt). All pharmacological treatments were given by force-feeding (gastric administration by a curved cannula) twice daily in non-anaesthetized animals. Rats were randomly included by pair (one in normoxia, one in hypoxia) in one of the four different groups of treatment. All drugs were solubilized in an acid glucose solution 5% (pH 3.5±0.5). A preliminary dose-response study (10, 20 , 30 mg/kg) was done to determine the optimal dose of carvedilol that decreases RVH. As regards prazosin and propranolol, to obtain a high level of α-or β-adrenergic blockade effects, a high dose equipotent to carvedilol was used [27, 39] , and administrated twice daily because of the short half-life of all these drugs. The objective was to reduce right ventricular systolic pressure (RVSP) in the same maximal proportion with all drugs with a maximal blockade of adrenergic pathways. Rats of each group were weighed at the beginning (day 0) after the 1st (D1), 2nd (D2), 3rd (D3), 4th (D4), 5th (D5), 7th (D7), 10th (D10), 12th (D12), and 14th day (D14).
Hemodynamics
After exposure to hypoxia, the animals were anaesthetized with pentobarbital [60 mg/kg intra-peritoneal (i.p.)]. Central temperature was monitored and maintained constant. Hemodynamic measurements were performed in normoxia according to the method of Rabinovitch et al. [28] and have been previously described in details [21] . Briefly, RVSP was measured by right internal jugular way with a polyethylene catheter with a curved tip (ATOM, Indwelling feeding tube for infant, 4Fr) placed in the right ventricular cavity. RVSP was assumed to be equal to the pulmonary arterial systolic pressure. Mean systemic arterial blood pressure (MABP) was measured via a polyethylene catheter (A-M Systems, Carlsborg, Washington, USA) in a carotid artery, by a pressure transducer [Spectramed (Statham), P23XL, Munich, Germany] and an electronic recording system (GOULD, SC1012, Cleveland, Ohio, USA). Heart rate (HR) was obtained from the pressure signal. Cardiac output (CO) was obtained via a thermocouple microprobe introduced in the left carotid artery in replacement of the systemic pressure catheter (Thermocouple Copper-Constantan, 0.025-in. diameter, PHYMEP, Paris, France) and measured by thermodilution with a cold (15°C) saline injection of 300 μl in the right ventricle (Cardiotherm 400, Columbus instruments, Columbus, Ohio, USA). All hemodynamics procedures and biological measures were completed within 30 min. O 2 ) was calculated as
. Hematocrit was measured on venous blood using a microcentrifuge (Microspin, Ames, Bayer diagnostic, Leverkusen, Germany).
Cardiac morphometrics and pulmonary histological measurements
After the physiological measurements, all anaesthetized rats were euthanized by rapidly removing the heart before separating the right ventricle from the left ventricle + septum, which were weighed [21] . The Fulton's ratio, defined as the right-to-left ventricular weight ratio was calculated.
Evaluation of pulmonary vascular remodeling
After dissection of the heart, the lungs were fixed in distended state by an intra-tracheal injection of a 4% aqueous buffered formalin solution at a pressure of 25 cmH 2 O and rinsed of its blood [8] . The entire specimen was then immersed in a bath of the same fixative for 1 week. A transversal slice of the right lower lobe of each lung was processed for paraffin embedding and 4-μm thick sections were stained with hematoxylin-phloxin-saffron for light microscopy. For each rat (n=10 for each group), all intra-acinar distal pulmonary arteries were numbered and analyzed in a blind manner to assess the external diameter of the arteries and their wall thickness index (WTI).
Distribution of the wall thickness index
The external diameter (distance between and including the two external elastic laminae intersected by the diameter) and the medial thickness (distance from the luminal surface of the internal elastic laminae to the abluminal surface of the external laminae) were evaluated in a mean of 78.9±2.9 (from 45 to 118) intra-acinar arteries of each rat. The WTI was calculated using the following formula [23] :
Statistical analysis
Data were expressed as mean±SE. The number of experiments is indicated on each figure and table. For all statistical studies, two-way analysis of variance (ANOVA), followed by a Fisher post-test, was used. Differences were considered to be statistically significant for P<0.05. Correlation between right ventricular weight (RVw) and RVSP was studied by regression lines in which the parallelism, by the intermediary of the ordinate value at y-axis intersection and director coefficient, was compared two by two.
Results
All measurements performed after 2 weeks of treatment were made in normoxia, either in normoxic (Nx) or in chronic hypobaric hypoxic (Hx) rats. Body weight ( Fig. 1 ) was lower in Hx vs Nx rats, independent of the treatment used (p<0.0001). Exposure to chronic hypoxia induced an increase (p<0.0001) in Fulton's ratio (Fig. 2a) , which was partially prevented by treatment (p<0.01, vs glucose). Chronic hypoxia led (p<0.0001) to RVH (Fig. 2b) , which was reduced (p<0.0001) only by carvedilol (HxCv) or propranolol (HxPp), compared to glucose (HxCt). Left ventricular weight (LVw, Fig. 2c ) decreased in all Hx vs Nx rats (p<0.05), except in hypoxic rats treated by prazosin (HxPz). The fall in LVw was more marked in hypoxic propranolol-treated rats while prazosin totally prevented this reduction of LVw. RVw and RVSP (pooled Nx and Hx values) were correlated in all groups (R≥0.7976), and there was a difference in slope and intercept between carvedilol or prazosin and glucose groups (Fig. 3) . These correlations indicated that for the same increase in pressure, the hypertrophic response was reduced in carvedilol or prazosin-treated rats. Hematocrit and blood hemoglobin concentration (Table 2) Blood hemoglobin concentration and hematocrit were higher in all Hx vs Nx groups (p<0.0001). Treatments in Nx groups had no effect on hemoglobin concentration or hematocrit, while in Hx groups, HxCt group had a lower hematocrit that those treated by propranolol (p<0.05), prazosin (p<0.001), and carvedilol (p<0.01).
Morphometric data of the pulmonary arteries
The number of intra-acinar arteries was increased in the HxPz group (84.9±5.3), compared to the HxCv group (68.9±6.2, p<0.05), with no difference with HxCt (73.6±4.6) and HxPp groups (76.1±7.0). The number of intra-acinar arteries in Nx-treated groups was not different from the NxCt group. Wall thickness index (WTI, Fig. 4 ) increased in Hx compared to Nx group (p<0.0001). In Hx groups, carvedilol induced a reduction in WTI when compared to all other groups (p<0.0001). WTI decreased in NxPz group, compared to all other Nx groups (p<0.001), while the opposite effect was found in Hx groups when compared to glucose and carvedilol (p<0.001). 
Discussion
The present study compared physiological, myocardial, and pulmonary arterial morphometric data in normoxic and chronic hypobaric hypoxic rats treated by α-, β-, or αβ-antagonists. For the first time, carvedilol (αβ-antagonist) was shown to reduce RVH, RVSP, and WTI of pulmonary arteries in rats exposed to chronic hypoxia. Prazosin had no effect on right ventricular weight, suggesting that the α-adrenergic pathway is not clearly involved in the development of right ventricular hypertrophy, as previously shown [23] . Both propranolol and carvedilol reduced right ventricular hypertrophy. However, as compared to propranolol, carvedilol modified the relationship between RVw and RVSP, possibly through a reduction of myocardial collagen deposition [40] . Carvedilol was chosen because of its beneficial effects in a majority of cardiovascular models, partly linked to its adrenergic antagonist effects. We compared carvedilol to an α-or a β-adrenergic antagonist with the same profile, for example, without β 1 Values are means±SE CO Cardiac output, HR heart rate, SV stroke volume, MABP mean systemic arterial blood pressure, SVR systemic vascular resistance, RVSP right ventricular systolic pressure, Nx groups of rats reared in normoxia, Hx groups of rats reared in chronic hypobaric hypoxia *P<0.05 or better, treatment vs glucose; **P<0.05 or better, Hx vs Nx; ***P<0.05 or better, propranolol vs carvedilol; ****p<0.05 or better, propranolol vs prazosin; *****p<0.05, prazosin vs carvedilol selectivity or sympathomimetic activity. It could have been also interesting to compare carvedilol with an antioxidant. Indeed, carvedilol and particularly its metabolites have been shown to have some effects on the oxidative stress associated with cardiovascular diseases [13, 43] . Antioxidants are potent drugs to reduce pulmonary hypertension in hypoxic models [16, 42] .
Morphometric parameters
Carvedilol and prazosin blunted the relationship between RVw and RVSP, possibly through the α-adrenergic antagonist effect shared by the two molecules. Although Fulton's ratio was decreased in the same proportion than in all chronic hypoxic-treated groups, its two components RVw and LVw were greater in prazosin than in other treated groups. While α-adrenergic antagonists have been shown to induce cardiomyocyte hypertrophy in vitro [2, 17] , α-adrenergic antagonists, such as prazosin, hardly showed a reduction in ventricular hypertrophy in vivo. Thus, in human studies, prazosin failed to reduce left ventricular hypertrophy in spite of a clear decrease in essential systemic hypertension [14] . In spontaneous hypertensive rats, doxazosin failed to reduce left ventricular hypertrophy in spite of significant systemic arterial pressure reduction referring to a class effect [1] . In another study in patients with pulmonary arterial hypertension, doxazosin reduced left ventricular mass but failed to reduce right ventricular mass [23] . Currently, no study is available on the effects of prazosin on cardiac morphometric parameters in chronic hypoxia. Hypoxia decreased left ventricular weight in all groups except prazosin. This left ventricular hypotrophy has been associated with a reduction in oxidative capacity, [24] but it could also be linked to the general decrease in body weight [21] . The ability of carvedilol to reduce left ventricular weight is smaller than propranolol. This could be explained by the offset of the β-adrenergic antagonist action by the opposite α-adrenergic action on the left ventricular weight, as demonstrated by the absence of effect of chronic hypoxia on the left ventricular weight in the prazosin group. Carvedilol and propranolol partially reduced the RVH, possibly through a β-adrenergic antagonist effect [22, 25, 26] . The α-adrenergic antagonist prazosin had no effect on right ventricular hypertrophy, therefore, the similar efficacy of carvedilol, in comparison with propranolol, could be explained by its β-adrenergic antagonist action only. As previously shown, RVw was correlated to RVSP [28] . α-antagonists (prazosin and carvedilol) induced an uncoupling between the RVH process and the increase in afterload due to pulmonary arterial hypertension. While the α-antagonists decrease ventricular afterload, they are not able to reduce right ventricular mass, suggesting that they have a direct effect on the development of hypertrophy in the right as well as in the left ventricle.
Hemodynamics
Although adrenergic antagonists partially reduced RVSP [26] and RVH, other hemodynamical effects are not explained by a clear α-or β-antagonist action. RVSP more than doubled in chronic hypoxic control groups, in comparison with normoxic counterparts, which is slightly higher than previously described in the literature, but with a different methodology [28, 44] . CO was decreased in all treated normoxic groups, compared to control group. This can be explained by the action of β-adrenoceptor antagonists (propranolol and carvedilol), but not by the vasodilator action of α-antagonists, such as prazosin, which usually maintains CO in human use.
All present measurements were done under anesthesia by pentobarbital, which decreases sympathetic nervous activity [33] , and, thus, CO, in comparison with conscious state [10] ; however, all groups of rats received the same anesthesia. In control groups, chronic hypoxia decreased CO. It should be emphasized that all measurements were made in normoxia, so that the increased arterial O 2 content in chronic hypoxic rats for the same V : O 2 , is compatible with a reduced CO. In chronic hypoxic rats, CO was preserved in carvedilol, in comparison with propranololtreated group. In another model, cardiac failure, carvedilol is well-known to preserve CO, with an increase in stroke volume (SV), which compensates the decrease in HR [3] . Stroke volume decreased in the same way than CO in all normoxic-treated groups, probably via the negative inotropic effect of β-adrenergic antagonists carvedilol and propranolol but not by prazosin. The reduction of SV by prazosin could be explained by the α-adrenergic inotropic effect [12] .
Blood gases and oxygen-transport variables
The increased CaO 2 in chronic hypoxic rats accounts for the increase in CvO 2 and PvO 2 . The reasons for the reduction in V : O 2 are not clear. As arterio-venous difference remained stable between normoxic groups, we assumed that basal metabolism was reduced. It cannot be explained by the anaesthetic regimen, which was similar for each group of rat; the central temperature was monitored and maintained constant. PaO 2 is increased in chronic hypoxic rats, especially in propranolol and prazosin groups, probably through an amelioration of ventilation/perfusion ratio linked to changes in pulmonary artery pressures, in disagreement with the literature for prazosin [38] .
Morphometric data of the pulmonary arteries
For the first time, it was evidenced that carvedilol reduces arterial wall hypertrophy, as shown by the changes in WTI in chronic hypoxic rats, whereas no effect was demonstrated with prazosin and propranolol. Right ventricular systolic hypertension, but not WTI, was reduced by all antagonists, suggesting that carvedilol may have a specific effect on pulmonary remodeling, as previously demonstrated in systemic vascular smooth muscle cells [37] .
In conclusion, only carvedilol was able to show the following (four) effects: 1) decrease in chronic hypoxiainduced RVH, 2) decrease in RVSP, 3) decrease in the slope of the relationship between RVH and RVSP, and 4) reduction in pulmonary arterial wall hypertrophy. Propranolol reduced RVH and RVSP, while prazosin reduced RVSP and the relationship between RVH and RVSP. This study clearly shows that the sympathetic nervous system has a significant contribution to the development of right ventricular hypertrophy by a direct action on the myocardium and/or an indirect effect on pulmonary vasoconstriction, remodeling, and pulmonary hypertension. However, it does not allow clear distinction between these direct and indirect mechanisms. Carvedilol has demonstrated specific effects that could be linked to no other than adrenergic antagonist effects, such as anti-oxidant, anti-myocardial collagen deposition, and antiproliferative properties on vascular smooth muscle cells.
